SCHEDULE: Vanguard Group Reports Zero Beneficial Ownership in Ionis Pharma
Beneficial Ownership Update
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Ionis Pharmaceuticals Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 14 to Schedule 13G regarding its holdings in Ionis Pharmaceuticals Inc. common stock.
- The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the common stock of Ionis Pharmaceuticals Inc.
- This change is a direct result of an internal realignment within The Vanguard Group, which became effective on January 12, 2026.
- Following this realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions, in accordance with SEC Release No. 34-39538.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, procedural filing. It reflects an internal reporting change by The Vanguard Group rather than a change in investment thesis for Ionis Pharmaceuticals or a performance update.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that this filing reflects a common practice among large institutional investors like The Vanguard Group to periodically realign internal reporting structures, often to comply with regulatory interpretations or optimize internal management. This specific disaggregation of beneficial ownership reporting is a procedural change for Vanguard and does not inherently reflect a change in investment strategy towards Ionis Pharmaceuticals by Vanguard's underlying funds or managed accounts, which will now report separately.
Key Dates
| Date | Description |
|---|---|
| 1998-01-12 | Date of SEC Release No. 34-39538, which provides guidance on disaggregated reporting. |
| 2026-01-12 | Effective date of The Vanguard Group's internal realignment. |
| 2026-03-13 | Date of event which required the filing of this statement (change in beneficial ownership reporting). |
| 2026-03-27 | Date the Schedule 13G/A was signed by The Vanguard Group. |
Keywords
Ionis Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.